Search or filter publications

Filter by type:

Filter by publication type

Filter by year:

to

Results

  • Showing results for:
  • Reset all filters

Search results

  • Journal article
    Alrezaihi A, Penrice-Randal R, Dong X, Prince T, Randle N, Semple MG, Openshaw PJM, MacGill T, Myers T, Orr R, Zakotnik S, Suljič A, Avšič-Županc T, Petrovec M, Korva M, AlJabr W, Hiscox JA, ISARIC4C Investigatorset al., 2023,

    Enrichment of SARS-CoV-2 sequence from nasopharyngeal swabs whilst identifying the nasal microbiome

    , Journal of Clinical Virology, Vol: 171, ISSN: 1386-6532

    Simultaneously characterising the genomic information of coronaviruses and the underlying nasal microbiome from a single clinical sample would help characterise infection and disease. Metatranscriptomic approaches can be used to sequence SARS-CoV-2 (and other coronaviruses) and identify mRNAs associated with active transcription in the nasal microbiome. However, given the large sequence background, unenriched metatranscriptomic approaches often do not sequence SARS-CoV-2 to sufficient read and coverage depth to obtain a consensus genome, especially with moderate and low viral loads from clinical samples. In this study, various enrichment methods were assessed to detect SARS-CoV-2, identify lineages and define the nasal microbiome. The methods were underpinned by Oxford Nanopore long-read sequencing and variations of sequence independent single primer amplification (SISPA). The utility of the method(s) was also validated on samples from patients infected seasonal coronaviruses. The feasibility of profiling the nasal microbiome using these enrichment methods was explored. The findings shed light on the performance of different enrichment strategies and their applicability in characterising the composition of the nasal microbiome.
  • Journal article
    Swets MC, Kerr S, Scott-Brown J, Brown AB, Gupta R, Millar JE, Spata E, Mccurrach F, Bretherick AD, Docherty A, Harrison D, Rowan K, Young N, Groeneveld GH, Dunning J, Nguyen-Van-Tam JS, Openshaw P, Horby PW, Harrison E, Staplin N, Semple MG, Lone N, Baillie JKet al., 2023,

    Evaluation of pragmatic oxygenation measurement as a proxy for Covid-19 severity

    , NATURE COMMUNICATIONS, Vol: 14
  • Journal article
    McNally P, Lester K, Stone G, Elnazir B, Williamson M, Cox D, Linnane B, Kirwan L, Rea D, O'Regan P, Semple T, Saunders C, Tiddens HAWM, McKone E, Davies JCet al., 2023,

    Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Trial

    , AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 208, Pages: 917-929, ISSN: 1073-449X
  • Journal article
    Campion NJ, Villazala-Merino S, Thwaites RS, Stanek V, Fd HK, Pertsinidou E, Zghaebi M, Toth J, Fröschl R, Perkmann T, Gangl K, Schneider S, Ristl R, Scott IC, Cohen ES, Molin M, Focke-Tejkl M, Regelsberger G, Hansel TT, Valenta R, Eckl-Dorna J, Niederberger-Leppin Vet al., 2023,

    Nasal IL-13 production identifies patients with late phase allergic responses

    , Journal of Allergy and Clinical Immunology, Vol: 152, Pages: 1167-1178.E12, ISSN: 0091-6749

    BACKGROUND: There is limited knowledge on how local cytokine secretion patterns after nasal allergen challenge correlate with clinical symptoms especially with regards to the "late allergic response" (LAR) which occurs in approximately 40-50% of allergic patients. OBJECTIVE: In this study we aimed to characterise the immunological and clinical nasal responses to birch pollen allergen challenge with a special focus on the LAR. METHODS: In this randomised double-blinded placebo-control trial, birch pollen allergic participants were challenged with pollen extract (n=20) or placebo (n=10) on three consecutive days. On days one and three nasal secretions were collected at selected time points over a 24h time course for the measurement of 33 inflammatory mediators. Clinical responses were determined through subjective symptom scores and objective nasal airflow measurements. RESULTS: Provoked participants had significantly greater clinical responses and showed significant increases in tryptase and sST2 within minutes compared to placebo. Eight out of 20 provoked participants displayed high IL-13 levels 2-8 hours after allergen provocation. This group also showed significant changes in clinical parameters, with a secondary drop in nasal airflow measured by peak nasal inspiratory flow and increased symptoms of nasal obstruction which significantly differed from IL-13 non responders at 6 hours. CONCLUSION: IL-13 response status correlates with cytokine and clinical responses in the late phase after allergen provocation.
  • Journal article
    Southern KW, Burgel P-R, Castellani C, De Boeck K, Davies JC, Dunlevy F, Fajac I, Gramegna A, Lammertyn E, Middleton PG, Ratjen F, van Koningsbruggen-Rietschel Set al., 2023,

    Standards for the care of people with cystic fibrosis (CF)

    , Journal of Cystic Fibrosis, Vol: 22, Pages: 961-962, ISSN: 1569-1993
  • Journal article
    Taylor-Cousar JL, Boyd AC, Alton EWFW, Polineni Det al., 2023,

    Genetic therapies in cystic fibrosis

    , CURRENT OPINION IN PULMONARY MEDICINE, Vol: 29, Pages: 615-620, ISSN: 1070-5287
  • Journal article
    C-MOREPHOSP-COVID Collaborative Group, 2023,

    Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study

    , The Lancet Respiratory Medicine, Vol: 11, Pages: 1003-1019, ISSN: 2213-2600

    INTRODUCTION: The multiorgan impact of moderate to severe coronavirus infections in the post-acute phase is still poorly understood. We aimed to evaluate the excess burden of multiorgan abnormalities after hospitalisation with COVID-19, evaluate their determinants, and explore associations with patient-related outcome measures. METHODS: In a prospective, UK-wide, multicentre MRI follow-up study (C-MORE), adults (aged ≥18 years) discharged from hospital following COVID-19 who were included in Tier 2 of the Post-hospitalisation COVID-19 study (PHOSP-COVID) and contemporary controls with no evidence of previous COVID-19 (SARS-CoV-2 nucleocapsid antibody negative) underwent multiorgan MRI (lungs, heart, brain, liver, and kidneys) with quantitative and qualitative assessment of images and clinical adjudication when relevant. Individuals with end-stage renal failure or contraindications to MRI were excluded. Participants also underwent detailed recording of symptoms, and physiological and biochemical tests. The primary outcome was the excess burden of multiorgan abnormalities (two or more organs) relative to controls, with further adjustments for potential confounders. The C-MORE study is ongoing and is registered with ClinicalTrials.gov, NCT04510025. FINDINGS: Of 2710 participants in Tier 2 of PHOSP-COVID, 531 were recruited across 13 UK-wide C-MORE sites. After exclusions, 259 C-MORE patients (mean age 57 years [SD 12]; 158 [61%] male and 101 [39%] female) who were discharged from hospital with PCR-confirmed or clinically diagnosed COVID-19 between March 1, 2020, and Nov 1, 2021, and 52 non-COVID-19 controls from the community (mean age 49 years [SD 14]; 30 [58%] male and 22 [42%] female) were included in the analysis. Patients were assessed at a median of 5·0 months (IQR 4·2-6·3) after hospital discharge. Compared with non-COVID-19 controls, patients were older, living with more obesity, and had more comorbidities. Multiorgan abnormalities on MR
  • Journal article
    Postma MJ, Cheng C-Y, Buyukkaramikli NC, Pastor LH, Vandersmissen I, Van Effelterre T, Openshaw P, Simoens Set al., 2023,

    Reply to Standaert, B. Comment on "Postma et al. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium"

    , VACCINES, Vol: 11
  • Journal article
    Goss C, Culley F, Parthasarathy P, MacLeod K, McGregor A, Murphy K, Owen B, Sam Aet al., 2023,

    New Teaching and Assessment Practices in an Undergraduate Medicine Intercalated BSc in Endocrinology

    , Endocrine Abstracts
  • Conference paper
    Liew F, Efstathiou C, Fontanella S, Greenhalf W, Richardson M, Saunders R, Evans RA, Wain LV, Brightling C, Turtle L, Thwaites RS, Openshaw PJMet al., 2023,

    Late Breaking Abstract - Large scale phenotyping of long COVID inflammation reveals mechanistic subtypes of disease

    , Annual congress of the European-Respiratory-Society (ERS), Publisher: European Respiratory Society, ISSN: 0903-1936

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://www.imperial.ac.uk:80/respub/WEB-INF/jsp/search-t4-html.jsp Request URI: /respub/WEB-INF/jsp/search-t4-html.jsp Query String: id=860&limit=10&resgrpMemberPubs=true&page=12&respub-action=search.html Current Millis: 1768558168444 Current Time: Fri Jan 16 10:09:28 GMT 2026
Read the HIC-Vac blog
  • News
  • Interview

An interview with Professor Openshaw

Professor Peter Openshaw is interviewed by the Infectious Diseases Hub on influenza and immunopathogenesis